Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

Summary

The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.

Timeline

Start

2026-03-02

Primary completion

2027-11-30

Completion

2027-11-30

Drugs

Indications